OSE Immunotherapeutics Reports First Half 2020 Results and Corporate Update

    NEXT STORY
    Onxeo Reports its Financial Results for the First Half of 2020 and Provides an Update on its Activities
    PREV STORY
    MiMedx Concludes Enrollment for Phase 3 Plantar Fasciitis Trial
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chief Operating Officer

    NOVATO, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a ...

    author_avatar
    NASDAQ Market News

    ALK’s partner for Japan, Torii, secures pricing for new Japanese cedar SLIT-tablet

    author_avatar
    NASDAQ Market News

    Dr. Larry P. Tilley Joins World Organization as Advisory Board Member

    author_avatar
    NASDAQ Market News